RxDoctor Payments Data

Grace Ruidera, MD

Internal Medicine · Midwest City, OKNPI 1407886492

Payments from drug & device makers

$5,315in general payments, 2019–2025

Across 301 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$990
  • Novo Nordisk$726
  • AstraZeneca$548
  • Lilly USA, LLC$543
  • GSK$393
  • Abbott$284
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,25699%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,315 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$234,498
Medicare patients
588
Services billed
3,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin294$299,971
OzempicSemaglutide94$123,225
FarxigaDapagliflozin Propanediol79$87,952
RybelsusSemaglutide53$87,267
MounjaroTirzepatide47$72,810
TrulicityDulaglutide33$62,041
JanuviaSitagliptin Phosphate45$43,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$39,452
EliquisApixaban31$26,204
Tresiba Flextouch U-100Insulin Degludec28$19,714
MyrbetriqMirabegron18$15,684
XareltoRivaroxaban13$12,606
Levothyroxine Sodium718$9,047
Humalog Kwikpen U-100Insulin Lispro33$6,131
Omeprazole310$5,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$166$299,971294 claims
Novo NordiskOzempic, Rybelsus$726$210,492147 claims
Lilly USA, LLCMounjaro, Trulicity$543$134,85180 claims
AstraZenecaFarxiga$548$87,95279 claims
MerckJanuvia$127$43,27045 claims
GSKTrelegy Ellipta$393$39,45235 claims
PfizerEliquis$263$26,20431 claims
Johnson & JohnsonXarelto$18$12,60613 claims
AbbVieSynthroid$990$2,78357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →